PAN THERAPEUTICS
Pan Therapeutics develops novel virus-based anti-cancer drugs for the treatment of cancer patients and domestic pets.
PAN THERAPEUTICS
Industry:
Health Care Therapeutics Wellness
Address:
Epalinges, Vaud, Switzerland
Country:
Switzerland
Total Employee:
1+
Status:
Active
Total Funding:
10 K CHF
Investors List
Venture Kick
Venture Kick investment in Grant - Pan Therapeutics
More informations about "Pan Therapeutics"
PanTera - A better fight for life
PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors.. PanTera aims to secure the large-scale production of actinium-225 (Ac-225), …See details»
Pan Therapeutics - Funding, Financials, Valuation & Investors
Pan Therapeutics develops novel virus-based anti-cancer drugs for the treatment of cancer patients and domestic pets. New. Resources. Advanced Search. Start Free Trial . ... How …See details»
Pan Therapeutics - PitchBook
What industry is Pan Therapeutics in? Pan Therapeutics’s primary industry is Drug Discovery. Is Pan Therapeutics a private or public company? Pan Therapeutics is a Private company. What …See details»
Pan Therapeutics: Drug pipelines, Patents, Clinical trials - Synapse
Jul 9, 2023 Explore Pan Therapeutics with its drug pipeline, therapeutic area, technology platform, 8 literature.See details»
Kenneth Lundstrom, CEO, Pan Therapeutics
Kenneth Lundstrom, CEO, Pan Therapeutics Dr. Kenneth Lundstrom has a broad expertise in gene expression, viral vectors and gene therapy. He received his Ph.D. in molecular genetics …See details»
PanTher Therapeutics
Aug 13, 2024 PanTher Therapeutics Receives FDA Clearance of IND Application for Phase 1b Study of PTM-101 for the Localized Treatment of Pancreatic Cancer. Read More. April 8, 2024. PanTher Therapeutics Presents …See details»
Pan Therapeutics - Crunchbase
Pan Therapeutics develops novel virus-based anti-cancer drugs for the treatment of cancer patients and domestic pets. Search Crunchbase. Start Free Trial . Chrome Extension. …See details»
Panavance - Novel Cancer Therapeutic - Giving …
Panavance Therapeutics Provides Update on Phase 1 Clinical Trial of Misetionamide in Pancreatic Cancer at 2024 Visceral Medicine Congress Press Release – August 14, 2024 Panavance Therapeutics Announces …See details»
Viral vectors engineered for gene therapy - PubMed
1 Pan Therapeutics, Lutry, Switzerland. Electronic address: [email protected]. PMID: 37541721 DOI: 10.1016/bs.ircmb.2023.05.005 Abstract Gene therapy has seen major …See details»
PAN-TB Collaboration to Advance Investigational Tuberculosis …
Aug 17, 2022 The planned phase 2 trials that will be supported by the JDA were designed by the PAN-TB collaboration and informed by the World Health Organization’s (WHO) recently …See details»
Government of Canada announces new clinical trials consortium, …
Jan 19, 2023 This Pan-Canadian consortium is receiving $39M for its activities. Seven training platforms are receiving a combined investment of over $32M to train a new generation of …See details»
PAN-TB Collaboration to Advance Investigational Tuberculosis …
Aug 17, 2022 The PAN-TB collaboration plans to work closely and transparently with the European Regimen Accelerator for Tuberculosis (ERA4TB), which was launched in January …See details»
Tour of Scotland: Tay Therapeutics is a product of University of …
Mar 11, 2025 Founder and CEO Andrew Woodland describes how they made the decision to focus on inflammation for the pan-BET, which is partnered with VYNE Therapeutics. VYNE …See details»
Pan Cancer - Crunchbase Company Profile & Funding
Pan-Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company …See details»
Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s ...
Commenting on the acquisition, Epsilogen CEO Tim Wilson said: “We are excited to create the world’s leading pan-isotype antibody company with the goal of bringing improved therapeutics …See details»
Pan-Cancer Omics Study Reveals New Therapeutic Targets
Jun 26, 2024 Tumor and data types of the CPTAC pan-cancer database. [Li, Yize, et al., Proteogenomic data and resources for pan-cancer analysis, Cancer Cell, 2023] In this study, …See details»
PAN-TB Collaboration to Advance Investigational Tuberculosis …
August 17, 2022 – The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) …See details»
Pan-cancer proteogenomics characterization of tumor immunity
Immunotherapy holds strong promise for cancer treatment but at present benefits only a small proportion of cases. A pan-cancer analysis of the immune landscape in more than 1,000 …See details»
FDA Approves New Treatment for PNETs: What You Need to Know
Mar 31, 2025 The U.S. Food & Drug Administration has granted approval for a new drug to treat pancreatic neuroendocrine tumors, also called PNET or PanNET. “I am delighted that patients …See details»
Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s ...
2 days ago Commenting on the acquisition, Epsilogen CEO Tim Wilson said: "We are excited to create the world’s leading pan-isotype antibody company with the goal of bringing improved …See details»